Use of Topical Finasteride Vs Systemic Finasteride in Male Pattern Baldness

Download Article

DOI: 10.21522/TIJAR.2014.08.02.Art003

Authors : R V Kumar, M S Abirami

Abstract:

In this study we have analyzed the use of finasteride which is a type P-selective 5a-reductase inhibitor. By decreasing dihydroxytestestrone (DHT) level, it is found to be effective in the treatment of male androgenic alopecia. In this study, we compared the effect of topical vs. systemic finasteride in the treatment of androgenic alopecia.  Our study is a randomized clinical trial study having 30 male patients. They have come for alopecia treatment at Nesam hospital, Coimbatore, India. We have selected male patients with androgenic alopecia and divided them into two groups (A, B), randomly having 15 patients in each group. For group A, Topical finasteride (0.1%) with minoxidil (5%) solution was given. Group B patients received topical minoxidil with oral finasteride (1mg) tablets. All patients were regularly followed up till the end of 6 months. A Patient had a first review in the first week followed by monthly follow up. Following parameters were taken into account: size of bald area, total hair count, and terminal hair. Data was analyzed by Chi-square statistical test. Each month the terminal hair, size of bald area and hair count between the two groups were compared. In the initial few months group, A showed good improvement. But Serial measurements indicated that a significant increase in hair counts and terminal hair counts is seen in both groups.  This study showed that on long term follow-up of more than 3 months, both topical and systemic finasteride groups had similar results.

References:

[1] Lolli F, Pallotti F, Rossi A, Fortuna MC, et al -2017 Androgenetic alopecia: a review. Endocrine. 2017;57(1):9–17. [PubMed] [Google Scholar].

[2] Inui S, Itami S-2012. Androgen actions on the human hair follicle: perspectives. ExpDermatol. doi:10.1111/exd.12024 [PubMed].

[3] El-Domyati M, Attia S, Saleh F, et al - 2009 Androgenetic alopecia in males: a histopathological and ultrastructural study. J CosmetDermatol. 2009; 8(2)83–91.

[4] Noubarani M, Rostamkhani H, Erfan M, Kamalinejad M, Eskandari MR, Babaeian M, Salamzadeh J. – 2014, Effect of adiantum capillus veneris linn on an animal model of testosterone-induced hair loss. Iran J Pharm Red. Winter; 13(Suppl): 113–118.

[5] Trueb RM.- 2002 Molecular mechanisms of androgenetic alopecia. Ther Umsch ;59(5) 211–6.

[6] Finn DA, Beadles-Bohling AS, Beckley EH, et al – 2006.A new look at the 5alpha-reductase inhibitor finasteride. Cns Drug Rev; 12:53–76.

[7] Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM & Vena (1997) Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course, Journal of Dermatological Treatment, 8:3, 189-192, DOI: 10.3109/09546639709160517.

[8] Caserini M, Radicioni M, Leuratti C, et al – 2016, Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J ClinPharmacolTher; 54(1):19–27.

[9]    Robinson J Published December 18, 2016. Accessed July 04, 2017.  Hair transplant: what to expect–/skin-problems-and-treatments/hair-loss/men-hair-loss17/hair transplant/WebMD https://www.webmd.com.

[10] Dunlop F. 2005- Androgenetic alopecia in men
and women: An overview of cause and treatment. Available from: http://www.folicle.comsection 22.html.

[11] Rafi AW, Katz RM – 2011, Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatol. 2011; 241953.

[12]             Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009 Jan-Feb;75(1):47-51. doi: 10.4103/0378-6323.45220. PMID: 19172031.

[13] Caserini M, Radicioni M, Leuratti C, et al – 2014, A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther.;52(10):842–9.

[14] Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol. 2018;17(4):457-463.

[15] Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM & Vena - Received 23 Aug 1996, accepted 18 Mar 1997, Published online: 12 Jul 2009 - Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course Pages 189-192.

[16] Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD- 2002 Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, and daily. J Am Acad Dermatol; 46:517-23.

[17] Chandrashekar B S, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J 2015; 6:17-20.